Peroxisomal β-oxidation enzyme, DECR2, regulates lipid metabolism and promotes treatment resistance in advanced prostate cancer.
Chui Yan MahAn Dieu Trang NguyenTakuto NiijimaMadison HelmJonas DehairsFeargal Joseph RyanNatalie RyanLake-Ee QuekAndrew J HoyAnthony S DonIan G MillsJohannes V SwinnenDavid John LynnZeyad D NassarLisa M ButlerPublished in: British journal of cancer (2024)
Our findings support a focus on perFAO, specifically DECR2, as a promising therapeutic target for CRPC and as a novel strategy to overcome lethal treatment resistance.